Mucormycotic slough of nasal floor and palate in the anephric patient

Gluskin, Melvin; Solomon, Marshal P.; Gold, Burton M.; Corrado, Michael L.; Berger, Jules

doi:10.14219/jada.archive.1979.0488

Cited by 20 publications

(7 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the first dialysis patient with mucormycosis, reported by Gluskin et al [17], was not noted to be receiving deferoxamine, subsequent cases of mucormycosis in patients undergoing dialysis have been in those receiving deferoxamine for aluminum or iron excess [6][7][8][9][10][11][12][13]15]. In addition to patients with renal failure, patients with hematologic disorders, all of whom were treated with deferoxamine, have been reported with mucormycosis [3][4][5]14,16].…”

Section: Resultsmentioning

confidence: 99%

Mucormycosis: association with deferoxamine therapy

Daly

Velázquez

Bradley

et al. 1989

The American Journal of Medicine

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Mucormycosis: association with deferoxamine therapy

Daly

Velázquez

Bradley

et al. 1989

The American Journal of Medicine

View full text Add to dashboard Cite

“…The infection is often associated with acidosis due to diabetes, diarrhea, or uremia. Diabetic acidosis was considered to be the predisposing condition in 50–70% of the reported patients with mucormycosis prior to the HIV pandemic (103,104). More recently it is commonly seen associated with HIV infection and AIDS (101,105).…”

Section: Oral Manifestations Of Uncommon Systemic Mycosesmentioning

confidence: 99%

“…Other important symptoms include blood‐tinged nasal discharge, unilateral facial pain, and numbness (107,108). Occasionally the most significant presenting symptom is necrotic ulceration or sloughing of the maxillary or palatal mucosa (103,109,110).…”

Section: Oral Manifestations Of Uncommon Systemic Mycosesmentioning

confidence: 99%

Candidiasis and other fungal diseases of the mouth

2002

View full text Add to dashboard Cite

The advent of the human immunodeficiency virus (HIV) and the increasing prevalence of immunocompromised individuals due to surgical and medical advances have resulted in a resurgence of opportunistic infections including oral candidiasis and other rare mycoses which were once considered exotic. It is now recognized that oral candidiasis may present in many clinical guises that may confound the unwary clinician. Other mycotic diseases such aspergillosis, cryptococcosis, histoplasmosis, and mucormycosis may manifest intraorally both as primary lesions and as secondary manifestation of systemic disease. The primary oral pathology of most of the latter mycoses is ulcerations that respond well to systemic therapy with the polyene, amphotericin B. In general, the management of oral fungal infections has been revolutionized by the triazole group of drugs, fluconazole and itraconazole, although recent reports indicate an alarming increase of resistant organisms in particular to fluconazole. The first part of this review attempts to provide an overview of clinical variants of oral candidiasis and current therapeutic techniques, while the latter part outlines the rare oral mycoses and their management.

show abstract

“…Prior to 1986, the development of mucormycosis in dialysis patients had been reported only once ( 1). Since then, a substantial number of such cases have been recognized in dialysis patients treated with deferoxamine B (DFO)' for either aluminum or iron overload.…”

mentioning

confidence: 99%